← Back to Search

Neuroprotectant

Nerinetide (NA-1) for Stroke (FRONTIER Trial)

Phase 3
Waitlist Available
Led By Jim Christenson, M.D.
Research Sponsored by NoNO Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights

FRONTIER Trial Summary

This trial will test whether nerinetide can help people with acute cerebral ischemia if given soon after symptoms start.

Eligible Conditions
  • Stroke

FRONTIER Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Modified Rankin Scale (mRS) scale
Secondary outcome measures
Barthel Index
Mortality rate
National Institutes of Health Stroke Scale (NIHSS)
+2 more

FRONTIER Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nerinetide (NA-1)Experimental Treatment1 Intervention
2.60 mg/kg of nerinetide (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
Group II: PlaceboPlacebo Group1 Intervention
Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nerinetide (NA-1)
2015
Completed Phase 3
~540

Find a Location

Who is running the clinical trial?

NoNO Inc.Lead Sponsor
5 Previous Clinical Trials
2,184 Total Patients Enrolled
3 Trials studying Stroke
2,140 Patients Enrolled for Stroke
Brain CanadaOTHER
17 Previous Clinical Trials
5,432 Total Patients Enrolled
3 Trials studying Stroke
198 Patients Enrolled for Stroke
Djavad Mowafaghian Centre for Brain HealthUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are receiving this therapy?

"That is correct, the information on clinicaltrials.gov affirms that this research is actively recruiting patients. The posting date was March 26th, 2015 and the most recent update was June 21st, 2022. The study seeks to enroll 586 individuals at 4 research sites."

Answered by AI

Are we still looking for patients for this trial?

"Yes. The website clinicaltrials.gov contains information that leads us to believe that the recruitment for this trial is still open. This trial was first posted on March 26th, 2015 and was most recently updated on June 21st, 2022. The goal is to recruit 586 participants from 4 different locations."

Answered by AI

Are there any ineligibility requirements for subjects in this research?

"This clinical trial is designed for patients with ischemia that are between 40 and 95 years old. Around 586 people will be accepted into the study."

Answered by AI

What is the official governmental stance on NA-1?

"NA-1's Phase 3 status indicates that there is some evidence of its efficacy, and thus our team at Power has given it a safety score of 3."

Answered by AI

Does this research project have an age limit? If so, what is the age limit?

"This study's inclusion criteria state that the minimum age for participants is 40, with the maximum age set at 95."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
2015. "Field Randomization of Nerinetide (NA-1) Therapy in Early Responders". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02315443.
~53 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top